Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLARGO Trial: Polatuzumab Vedotin + Rituximab, Gemcitabine, and Oxaliplatin in R/R DLBCL

76 views
June 14, 2022
Comments 0
Login to view comments. Click here to Login